So dose number 70 was added last December, and four months later we are headed for the addition of two more infant doses.
The FDA has approved Sanofi's Menactra for use in two doses at 9 and 15 months.
The ACIP has not yet added it to CDCs recommended schedule, but does anyone really think that they are not going to? No.
FDA Approvals Meningococcal Vaccine For Children
Jamie Peter | Web Producer
Posted: 8:01 pm EDT April 22, 2011
Updated: 8:29 pm EDT April 22, 2011
A local drug maker has been granted approval for a vaccine to protect infants against a potentially deadly disease.
Sanofi Pasteur announced Friday that the Food and Drug Administration (FDA) approved it's two-dose schedule for Menactra, a meningococcal conjugate vaccine, for children 9 months through 23 months.
It is the first U.S. approval of a meningococcal vaccine for this age group.
"Licensure of Menactra vaccine for infants as young as 9 months of age gives the opportunity to help protect infants against this potentially deadly disease when the likelihood of exposure supports a need for early protection," said Stephen I. Pelton, MD. Pelton is a professor of Pediatrics and Epidemiology at Boston University Schools of Medicine and is the Public Health and Chief for Pediatric Infectious Diseases at Boston Medical Center.
Meningococcal disease is rare but it can be deadly.
It is caused by the bacterium Neisseria meningitidis and can progress so quickly it can claim the life of a child within 24 hours.
FDA studies also showed that measles-mumps-rubella-varicella vaccine (MMRV) and pneumococcal conjugate vaccine (PCV7) can be administered with the Menactra vaccine in children.
Vaccine related reactions included swelling, tenderness at injection site, and irritability.